HOXB7 (E3H4S) Rabbit mAb #65130
- WB
- IF
- ChIP
Supporting Data
| REACTIVITY | H |
| SENSITIVITY | Endogenous |
| MW (kDa) | 27 |
| Source/Isotype | Rabbit IgG |
Application Key:
- WB-Western Blotting
- IF-Immunofluorescence
- ChIP-Chromatin Immunoprecipitation
Species Cross-Reactivity Key:
- H-Human
Product Information
Product Usage Information
| Application | Dilution |
|---|---|
| Western Blotting | 1:1000 |
| Immunofluorescence (Immunocytochemistry) | 1:200 - 1:800 |
| Chromatin IP | 1:50 |
Storage
Protocol
Specificity / Sensitivity
HOXB7 (E3H4S) Rabbit mAb recognizes endogenous levels of total HOXB7 protein. The antibody also detects a 20 kDa band of unknown origin.
Species Reactivity:
Human
Source / Purification
Monoclonal antibody is produced by immunizing animals with recombinant protein specific to the amino terminus of human HOXB7 protein.
Background
Homeobox (HOX) proteins are homeodomain transcription factors (1). They bind to sequence-specific DNA motifs (C/G)TAATTG and function as master transcriptional regulators, controlling the coordinated expression of genes involved in embryogenesis and tissue differentiation (1,2). HOXB7 belongs to the B group of HOX proteins and plays a dominant role in facilitating tumor progression in many solid tumors. Overexpression of HOXB7 is found in many types of tumors, including melanoma, ovarian, GI-tract, pancreatic ductal adenocarcinoma (PDAC), lung, gliomas, and breast cancers. Aberrant high expression of HOXB7 is associated with poor prognosis (3). The protein promotes tumor cell proliferation, angiogenesis, epithelial-mesenchymal transition, migration, and invasion, as well as drug resistance through regulation of multiple signaling pathways, such as MAPK, VEGF, FGF, TGF-β, and EGFR/Her2 (4-8). HOXB7 binding to a DNA promoter requires its interaction with a cofactor protein such as PBX2 or CBP for transcriptional activation of downstream targets (9,10). Disruption of the HOXB7/PBX complex formation by antagonist peptide HXR9 can inhibit HOXB7 function and is considered as a potential therapeutic value (11).
- Krumlauf, R. (1994) Cell 78, 191-201.
- Pellerin, I. et al. (1994) Mol Cell Biol 14, 4532-45.
- Errico, M.C. et al. (2016) Cancer Res 76, 2857-62.
- Joo, M.K. et al. (2016) World J Gastroenterol 22, 8247-8256.
- Carè, A. et al. (2001) Cancer Res 61, 6532-9.
- He, X. et al. (2017) Oncotarget 8, 1247-1261.
- Jin, K. et al. (2015) Cancer Discov 5, 944-59.
- Joo, M.K. et al. (2016) J Gastroenterol Hepatol 31, 1717-1726.
- Errico, M.C. et al. (2013) Int J Cancer 133, 879-92.
- Chariot, A. et al. (1999) Oncogene 18, 4007-14.
- Shen, L.Y. et al. (2019) Cancer Sci 110, 1735-1745.
Limited Uses
Except as otherwise expressly agreed in a writing signed by a legally authorized representative of CST, the following terms apply to Products provided by CST, its affiliates or its distributors. Any Customer's terms and conditions that are in addition to, or different from, those contained herein, unless separately accepted in writing by a legally authorized representative of CST, are rejected and are of no force or effect.
Products are labeled with For Research Use Only or a similar labeling statement and have not been approved, cleared, or licensed by the FDA or other regulatory foreign or domestic entity, for any purpose. Customer shall not use any Product for any diagnostic or therapeutic purpose, or otherwise in any manner that conflicts with its labeling statement. Products sold or licensed by CST are provided for Customer as the end-user and solely for research and development uses. Any use of Product for diagnostic, prophylactic or therapeutic purposes, or any purchase of Product for resale (alone or as a component) or other commercial purpose, requires a separate license from CST. Customer shall (a) not sell, license, loan, donate or otherwise transfer or make available any Product to any third party, whether alone or in combination with other materials, or use the Products to manufacture any commercial products, (b) not copy, modify, reverse engineer, decompile, disassemble or otherwise attempt to discover the underlying structure or technology of the Products, or use the Products for the purpose of developing any products or services that would compete with CST products or services, (c) not alter or remove from the Products any trademarks, trade names, logos, patent or copyright notices or markings, (d) use the Products solely in accordance with CST Product Terms of Sale and any applicable documentation, and (e) comply with any license, terms of service or similar agreement with respect to any third party products or services used by Customer in connection with the Products.